Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics

Drug Metabolism Reviews

Volumn 45, Issue 2, 2013, Pages 218-230

  Martinez, Marilyn N ^a   Antonovic, Leposava ^b   Court, Michael ^c   Dacasto, Mauro ^d   Fink Gremmels, Johanna ^e   Kukanich, Butch ^f   Locuson, Chuck ^g   Mealey, Katrina ^c   Myers, Michael J ^a   Trepanier, Lauren ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e UTRECHT UNIVERSITY   (Netherlands)

^f KANSAS STATE UNIVERSITY   (United States)

^g Pharmaprogressio Consulting   (United States)

Author keywords

Canine; Drug metabolism; Enzyme inhibitors; Enzyme substrates; Interspecies differences; Orthologs; Pharmacogenomics

Indexed keywords

ATIPAMEZOLE; CAFFEINE; CHLORAMPHENICOL; CIPROFLOXACIN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A13; CYTOCHROME P450 2A25; CYTOCHROME P450 2B11; CYTOCHROME P450 2C21; CYTOCHROME P450 2D15; CYTOCHROME P450 2E1; CYTOCHROME P450 3A12; ENROFLOXACIN; FLUVOXAMINE; FURAFYLLINE; KETOCONAZOLE; MAVACOXIB; METRONIDAZOLE; MICONAZOLE; OMEPRAZOLE; ONDANSETRON; PHENACETIN; THEOPHYLLINE; THIOTEPA; TICLOPIDINE; UNCLASSIFIED DRUG;

DOG; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; PHARMACOGENOMICS; PHARMACOKINETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS;

EID: 84876561670     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.765445     Document Type: Review

References (135)

1. Adams HR, Dixit BN. (1970). Prolongation of pentobarbital anesthesia by chloramphenicol in dogs and cats. J Am Vet Med Assoc 156: 902-905.
2. Aidasani D, Zaya MJ, Malpas PB, Locuson CW. (2008). In vitro drugdrug interaction screens for canine veterinary medicines: Evaluation of cytochrome P450 reversible inhibition. Drug Metab Dispos 36: 1512-158.
3. Antonovic L, Martinez M. (2011). Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: Where are we now Where are we going Future Med Chem 3: 855-879.
4. Ariyoshi N, Oguri K, Koga N, et al. (1995). Metabolism of highly persistent PCB congener, 2,4,5,20,40,50-hexachlorobiphenyl, by human CYP2B6. Biochem Biophys Res Commun 212: 455-460.
5. Aretz JS, Geyer J. (2010). Detection of the CYP1A2 1117C4T polymorphism in 14 dog breeds. J Vet Pharmacol Ther 34: 98-100.
6. Azuma R, Komuro M, Kawaguchi Y, et al. (2002). Comparative analysis of in vitro and in vivo pharmacokinetic parameters related to individual. variability of GTS-21 in canine. Drug Metab Pharmacokinet 17: 75-82.
7. Baratta MT, Zaya MJ, White JA, Locuson CW. (2010). Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-Administered in dogs. J Vet Pharmacol Ther 33: 50-55.
8. Benchaoui HA, Cox SR, Schneider RP, et al. (2007). The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther 30: 336-344. (Pubitemid 47024885)
9. Blaisdell J, Goldstein JA, Bai SA. (1998). Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26: 278-283. (Pubitemid 28182406)
10. Brown HS, Galetin A, Hallifax D. (2006). Prediction of in vivo drug-drug interactions from in vitro data: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45: 1035-1050. (Pubitemid 44436005)
11. Caraco Y, Sheller J, Wood AJ. (1999). Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 290: 413-422. (Pubitemid 29302351)
12. Case JB, Fick JL, Rooney MB. (2010). Proximal duodenal perforation in three dogs following deracoxib administration. J Am Animal Hosp Assoc 46: 255-258.
13. Chang Y, Fang WB, Lin SN, Moody DE. (2011). Stereo-selective metabolism of methadone by human liver microsomes and cDNAexpressed cytochrome P450s: A reconciliation. Basic Clin Pharmacol Toxicol 108: 55-62.
14. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. (1997). In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug. Metab Dispos 25: 1130-1136. (Pubitemid 27446582)
15. Chen CS, Lin JT, Goss KA, et al. (2004). Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65: 1278-1285. (Pubitemid 38543498)
16. Chen J, Tran C, Xiao L, et al. (2009). Co-induction of CYP 3A12 and 3A26 in dog liver slices by xenobiotics: Species difference between human and dog CYP3A induction. Drug Metab Lett 3: 61-66.
17. Ciaccio PJ, Duignan DB, Halpert JR. (1987). Selective inactivation by chloramphenicol of the major phenobarbital-inducible isozyme of dog liver cytochrome P-450. Drug Metab Dispos 15: 852-856. (Pubitemid 18019780)
18. Ciaccio PJ, Graves PE, Bourque DP, et al. (1991). cDNA and deduced amino acid sequences of a dog liver cytochrome P-450 of the IIIA gene subfamily. Biochem Biophys Acta 1088: 319-322.
19. Cook CS, Berry LM, Kim DH, et al. (2002). Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 30: 1344-1351. (Pubitemid 35397036)
20. Court MH, Hay-Kraus BL, Hill DW, et al. (1999). Propofol hydroxylation by dog liver microsomes: Assay development and dog breed differences. Drug Metab Dispos 27: 1293-1299.
21. Cox SR, Liao S, Payne-Johnson M, et al. (2011). Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther 34: 1-11.
22. Craig AJ, Seguela J, Queau Y, et al. (2006). Redefining the reference interval for plasma creatinine in dogs: Effect of age, gender, body weight and breed. J Vet Intern Med 20: 766.
23. D'mello A, Venkataramanan R, Satake M, et al. (1989). Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol 643: 441-454. (Pubitemid 19169541)
24. Desta Z, Wu GM, Morocho AM, Flockhart DA. (2002a). The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30: 336-343. (Pubitemid 34175027)
25. Desta Z, Zhao X, Shin JG, Flockhart DA. (2002b). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913-958. (Pubitemid 35168437)
26. Duignan DB, Sipes IG, Ciaccio PJ, Halpert JR. (1988). The metabolism of xenobiotics and endogenous compounds by the constitutive dog liver cytochrome P450 PBD-2. Arch Biochem Biophys 267: 294-304. (Pubitemid 19001032)
27. Eguchi K, Nishibe Y, Baba T, Ohno K. (1996). Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 26: 755-763.
28. Erickson DA, Mather G, Trager WF, et al. (1999). Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27: 1488-1495.
29. Fleischer S, Sharkey M, Mealey K, et al. (2008). Pharmacogenetic and metabolic differences between dog breeds: Their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS J 10: 110-119.
30. Fraser DJ, Feyereisen R, Harlow GR, Halpert JR. (1997). Isolation, heterologous expression, and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharm Exp Ther 283: 1425-1432. (Pubitemid 28016518)
31. Gerber JG, Rhodes RJ, Gal J. (2004). Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44. (Pubitemid 37532283)
32. Giantin M, Granato A, Morello EM, et al. (2010). Cytochromes P450 and ABC-transporters gene expression profiling in dog osteosarcoma, mast cell, and mammary gland tumours. Proceedings of the ESVONC Spring Congress, Torino, Italy, 59.
33. Giantin M, Vascellari M, Lopparelli RM, et al. (2013). Expression of the aryl hydrocarbon receptor pathway and cyclooxygenase-2 in dog tumors. Res Vet Sci 94: 90-99.
34. Gomez A, Ingelman-Sundberg M. (2009). Epigenetic and microRNAdependent control of cytochrome P450 expression: A gap between DNA and protein. Pharmacogenomics 10: 1067-1076.
35. Goodwin B, Moore LB, Stoltz CM, et al. (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60: 427-431. (Pubitemid 32781548)
36. Graham MJ, Bell AR, Crewe HK, et al. (2003). mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 33: 225-237. (Pubitemid 36408192)
37. Graham RA, Downey A, Mudra D, et al. (2002). In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos 30: 1206-1213. (Pubitemid 35265827)
38. Graham RA, Tyler LO, Krol WL, et al. (2006). Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes. J Biochem Mol Toxicol 20: 69-78.
39. Graves PE, Elhag GA, Ciaccio PJ. (1990). cDNA and deduced amino acid sequences of a dog hepatic cytochrome P450IIB responsible for the metabolism of 2,20,4,40,5,50-hexachlorobiphenyl. Arch Biochem Biophys 281: 106-115. (Pubitemid 20232879)
40. Greenbaum D, Colangelo C, Williams K, Gerstein M. (2003). Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4: 117.1-117.8.
41. Greger DL, Gropp FNC, Morel C, et al. (2006). Nuclear receptor and target gene mRNA abundance in duodenum and colon of dogs with chronic enteropathies. Domest Anim Endocrinol 31: 327-339. (Pubitemid 44528202)
42. Haller S, Schuler F, Lazic SE, et al. (2012). Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs. Drug Metab Dispos 40: 1603-1611.
43. Hasler JA, Harlow GR, Szklarz GD, et al. (1994). Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: Importance of amino acid residues 114, 290, and 363 for substrate specificity. Mol Pharmacol 46: 338-345. (Pubitemid 24271430)
44. Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, Court MH. (2000). Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: Breed and gender differences. Xenobiotica 30: 575-588. (Pubitemid 30449568)
45. Heikkinen AT, Friedlein A, Lamerz J, et al. (2012). Mass spectrometrybased quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in Beagle dog. Pharm Res 29: 1832-1842.
46. Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183.
47. Hofmann MH, Blievernicht JK, Klein K, et al. (2008). Aberrant splicing caused by single nucleotide polymorphism c.516G4T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325: 284-292. (Pubitemid 351439175)
48. Ingelman-Sundberg M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present, and future. Trends Pharmacol Sci 25: 193-200. (Pubitemid 38519910)
49. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C . (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526. (Pubitemid 350116943)
50. Intorre L, Mengozzi G, Maccheroni M, et al. (1995). Enrofloxacintheophylline interaction: Influence of enrofloxacin on theophylline steady-state pharmacokinetics in the Beagle dog. J Vet Pharmacol Ther 18: 352-356.
51. Jayyosi Z, Muc M, Erick J, et al. (1996). Catalytic and immunochemical characterization of cytochrome P450 isozyme induction in dog liver. Fundam Appl Toxicol 31: 95-102.
52. Johansson I, Ingelman-Sundberg M. (2011). Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 120: 1-13.
53. Kamimura H. (2006). Genetic polymorphism of cytochrome P450s in beagles: Possible influence of CYP1A2 deficiency on toxicological evaluations. Arch Toxicol 80: 732-738. (Pubitemid 44817811)
54. Kliewer S, Goodwin B, Willson TM. (2002). The nuclear pregnane X receptor: A key regulator of xenobiotics metabolism. Endocr Rev 23: 687-702. (Pubitemid 35191629)
55. Komori M, Shimada H, Miura T, Kamataki T. (1989). Interspecies homology of liver microsomal cytochrome P-450. A form of dog cytochrome P-450 (P-450-D1) crossreactive with antibodies to rat P-450-male. Biochem Pharmacol 38: 235-240. (Pubitemid 19033332)
56. Komura H, Iwaki M. (2008). Species differences in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97: 1775-1800.
57. Kouzmenko A, Ohtake F, Fujiki R, Kato S. (2010). Hormonal gene regulation through DNA methylation and demethylation. Epigenomics 2: 765-774.
58. Kukanich B, Coetzee JF, Gehring R, Hubin M. (2007). Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. J Vet Pharmacol Ther 30: 314-319. (Pubitemid 47024883)
59. Kukanich B, Kukanich KS, Rodriguez JR. (2011). The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. Vet Anaesth Analg 38: 224-230.
60. Kukanich B, Lascelles BDX, Aman AM, et al. (2005). The effects of inhibiting cytochrome P450, P-glycoprotein and gastric acid secretion on the oral bioavailability of methadone in dogs. J Vet Pharmacol Ther 28: 461-466. (Pubitemid 41530773)
61. Lamba J, Lamba V, Schuetz E. (2005). Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6: 369-383. (Pubitemid 41086769)
62. Larhammar D, Sundstrom G, Dreborg S, et al. (2009). Major genomic events and their consequences for vertebrate evolution and endocrinology. Ann N Y Acad Sci 1163: 201-208.
63. Lascelles BD, Blikslager AT, Fox SM, Reece D. (2005). Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 227: 1112-1117. (Pubitemid 41407339)
64. Liu YT, Hao HP, Liu CX, et al. (2007). Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 39: 699-721.
65. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408. (Pubitemid 34164012)
66. Locuson CW, Alfaro JF, Zaya MJ, et al. (2011). A non-Acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21. Drug Metab Lett 5: 253-258.
67. Locuson CW, Ethell BT, Voice M, et al. (2009). Evaluation of E. coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexprssed canine cytochrome P450 reductase. Drug Metab Dispos 37: 457-461.
68. Lu P, Singh SB, Carr BA, et al. (2005). Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther 313: 518-528. (Pubitemid 40604150)
69. Madeira M, Levine M, Chang TK, et al. (2004). The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 32: 460-467. (Pubitemid 38420282)
70. Mandsager RE, Clarke CR, Shawley RV, Hague CM. (1995). Effects of chloramphenicol on infusion pharmacokinetics of propofol in greyhounds. Am J Vet Res 56: 95-99.
71. Marathe PH, Rodrigues AD. (2006). In vivo animal models for investigating potential CYP3A-And Pgp-mediated drug-drug interactions. Curr Drug Metab 7: 687-704. (Pubitemid 44509676)
72. McLaughlin LA, Paine MJ, Kemp CA, et al. (2005). Why is quinidine an inhibitor of cytochrome P450 2D6 The role of key active-site residues in quinidine binding. J Biol Chem 280: 38617-38624. (Pubitemid 43853763)
73. McMillan SK, Boria P, Moore GE, et al. (2011). Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 239: 1084-1089.
74. Mealey KL. (2008). Canine ABCB1 and macrocyclic lactones: Heartworm prevention and pharmacogenetics. Vet Parasitol 158: 215-222.
75. Mealey KL, Jabbes M, Spencer E, Akey JM. (2008). Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38: 1305-1312.
76. Mills BM, Zaya MJ, Walters RR, et al. (2010). Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. Drug Metab Dispos 38: 396-404.
77. Mise M, Hashizume T, Komuro S. (2008). Characterization of substrate specificity of dog CYP1A2 using CYP1A2-deficient and wild-type dog liver microsomes. Drug Metab Dispos 36: 1903-1908.
78. Mise M, Hashizume T, Matsumoto S, et al. (2004a). Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 14: 769-773. (Pubitemid 39552792)
79. Mise M, Yadera S, Matsuda M, et al. (2004b). Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos 32: 240-245. (Pubitemid 38176942)
80. Mo SL, Liu YH, Duan W, et al. (2009). Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10: 730-753.
81. Nakamura A, Yamamoto Y, Tasaki T, et al. (1995). Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody. Drug Metab Dispos 23: 1268-1273.
82. Nebert DW, Russell DW. (2002). Clinical importance of the cytochromes P450. Lancet 360: 1155-1162. (Pubitemid 35246494)
83. Nelson DR. (2009). The cytochrome p450 homepage. Hum Genomics 4: 59-65.
84. Nishibe Y, Wakabayashi M, Harauchi T Ohno K. (1998). Characterization of cytochrome P450 (CYP 3A12) induction by rifampicin in dog liver. Xenobiotica 28: 545-557.
85. Niwa T, Murayama N, Yamazaki H. (2011). Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr Drug Metab 12: 412-435.
86. Ohno Y, Hisaka A, Suzuki H. (2007). General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46: 681-696. (Pubitemid 47204854)
87. Ohta KM, Motoya M, Komori M, et al. (1990). Interspecies homology of cytochrome P-450 purification and toxicological significance of a high spin form cytochrome P-450 (P-450-D2) from liver microsomes of polychlorinated biphenyl (PCB)-treated beagle dogs. J Biopharm Sci 1: 59-71.
88. Ohtsuki S, Schaefer O, Kawakami H, et al. (2012). Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities. Drug Metab Dispos 40: 83-92.
89. Oyama T, Kagawa N, Kunugita N, et al. (2004). Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9: 1967-1976. (Pubitemid 38918646)
90. Paine MF, Hart HL, Ludington SS, et al (2006). The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34: 880-886.
91. Pal D, Mitra AK. (2006). MDR and CYP3A4-mediated drug-herbal interactions. Life Sci 78: 2131-2145.
92. Parker HG, Kim LV, Sutter ND, et al. (2004). Genetic structure of the purebred domestic dog. Science 304: 1160-1164. (Pubitemid 38661853)
93. Paulson SK, Engel L, Reitz B, et al. (1999). Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27: 1133-1142. (Pubitemid 29463599)
94. Pedersen RS, Damkier P, Brosen K. (2005). Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study. Clin Pharmacol Ther 77: 458-467. (Pubitemid 40824959)
95. Raccor BS, Claessens AJ, Dinh JC, et al. (2012). Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab Dispos 40: 54-63.
96. Rodriguez-Antona C, Gomez A, Karlgren M, et al. (2010). Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 127: 1-17.
97. Roussel F, Duignan D, Lawton M, et al. (1998). Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357: 27-36. (Pubitemid 28402582)
98. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. (2004). Abundance of cytochromes P450 in human liver: A meta-Analysis. Br J Clin Pharmacol 57: 687-688.
99. Sahi J, Reyner EL, Bauman JN, et al. (2002). The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos 30: 135-140. (Pubitemid 34106531)
100. Sakamoto K, Kirita S, Baba T, et al. (1995). A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: Purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 319: 372-382.
101. Salavaggione OE, Kidd L, Prondzinski JL, et al. (2002). Canine red blood cell thiopurine S-methyltransferase: Companion animal pharmacogenetics. Pharmacogenetics 12: 713-724. (Pubitemid 36054938)
102. Sams RA, Muir WW. (1988). Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res 49: 245-249. (Pubitemid 18043402)
103. Sams RA, Muir WW, Detra RL, Robinson EP. (1985). Comparative pharmacokinetics and anesthetic effects of methohexital, pentobarbital, thiamylal, and thiopental in Greyhound dogs and non-Greyhound, mixed-breed dogs. Am J Vet Res 46: 1677-1683. (Pubitemid 15001478)
104. Sanders JE, Yeary RA, Fenner WR, Powers JD. (1979). Interaction of phenytoin with chloramphenicol or pentobarbital in the dog. J Am Vet Med Assoc 175: 177-180. (Pubitemid 9211463)
105. Savkur RS, Wu Y, Bramlett KS, et al. (2003). Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. Mol Genet Metab 80: 216-226. (Pubitemid 37272248)
106. Scott SA. (2011). Personalizing medicine with clinical pharmacogenetics. Genet Med 13: 987-995.
107. Shou M, Norcross R, Sandig G, et al. (2003). Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. Drug Metab Dispos 31: 1161-1169. (Pubitemid 37048288)
108. Stierlin H, Gaigle JW, Sallmann A, et al. (1979). Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 9: 601-610. (Pubitemid 10167099)
109. Sueyoshi T, Kawamoto T, Zelko I, et al. (1999). The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274: 6043-6046. (Pubitemid 29111006)
110. Takahashi H, Sato T, Shimoyama Y, et al. (1999). Potentiation of anticoagulant effect warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66: 569-681.
111. Tasaki T, Nakamura A, Itoh S, et al. (1998). Expression and characterization of dog CYP2D15 using baculovirus expression system. J Biochem (Tokyo) 123: 162-168. (Pubitemid 28068580)
112. Tenmizu D, Endo Y, Noguchi K, Kamimura H. (2004). Identification of the novel canine CYP1A2 1117 C4T SNP causing protein deletion. Xenobiotica 34: 835-846. (Pubitemid 39546272)
113. Tenmizu D, Noguchi K, Kamimura H, et al. (2006). The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor. Drug Metab Dispos 34: 800-806.
114. Teske RH, Carter GG. (1971). Effect of chloramphenicol on pentobarbital-induced anesthesia in dogs. J Am Vet Med Assoc 159: 777-780.
115. Tracy TS, Marra C, Wrighton SA, et al. (1996). Studies of flurbiprofen 40-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52: 1305-1309. (Pubitemid 26355306)
116. Turpeinen M, Ghiciuc C, Opritoui M, et al. (2007). Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica 37: 1367-1377. (Pubitemid 350146687)
117. Uchida T, Komori M, Kitada M, Kamataki T. (1990). Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated Beagle dogs. Mol Pharmacol 38: 644-651.
118. Van Beusekom CD, Schipper L, Fink-Gremmels J. (2010). Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. J Vet Pharmacol Ther 33: 519-527.
119. van de Sluis B, Peter AT, Wijmenga C. (2003). Indirect molecular diagnosis of copper toxicosis in Bedlington terriers is complicated by haplotype diversity. J Hered 94: 256-259. (Pubitemid 36828842)
120. Waller SC, He YA, Harlow GR, et al. (1999). 2,20,3,30,6,60- hexachlorobiphenyl hydroxylation by active site mutants of cytochrome P450 2B1 and 2B11. Chem Res Toxicol 12: 690-699. (Pubitemid 29398531)
121. Walsky RL, Obach RS. (2007). A comparison of 2-phenyl-2-(1-piperidinyl) propane (ppp), 1,10,100-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35: 2053-2059. (Pubitemid 350005195)
122. Wang H, Tompkins LM. (2008). CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9: 598-610.
123. Ward BA, Gorski JC, Jones DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306: 287-300. (Pubitemid 36734384)
124. Weber M. (2006). Influence of size on the dog's digestive function. Bull Acad Vét France 159: 327-332.
125. Whiterock VJ, Delmonte TA, Hui LE, et al. (2007). Frequency of CYP1A2 polymorphism in beagle dogs. Drug Metab Lett 1: 163-165.
126. Whiterock VJ, Morgan DG, Lentz KA, et al. (2012). Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs. Drug Metab Dispos 40: 228-231.
127. Yokose T, Doy M, Taniguchi T, et al. (1999). Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch 434: 401-411. (Pubitemid 29261528)
128. Zhang K, Kohno S, Kuroha M, et al. (2006a). Clinical oral doses of dexamethasone decreases intrinsic clearance of quinidine, a cytochrome P450 3A substrate in dogs. J Vet Med Sci 68: 903-907. (Pubitemid 44526548)
129. Zhang K, Kuroha M, Shibata Y, et al. (2006b). Effect of oral administration of clinically relevant doses of dexamethasone on regulation of cytochrome P450 subfamilies in hepatic microsomes from dogs and rats. Am J Vet Res 67: 329-334. (Pubitemid 43285610)
130. Zhang W, Roederer MW, Chen WQ, et al. (2012). Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics 13: 223-231.
131. Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9: 310-322.
132. Zhou SF. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clinical Pharmacokinet 48: 761-804.
133. Zhou D, Linnenbach AJ, Liu R, et al. (2010a). Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells. Drug Metab Dispos 38: 1015-1018.
134. Zhou SF, Wang B, Yang LP, Liu JP. (2010b). Structure, function, regulation, and polymorphism and the clinical significance of human cytochrome P450 1A2. Metab Rev 42: 268-354.
135. Zhou SF, Yang LP, Zhou ZW, et al. (2009). Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11: 481-494.